Specifying a Second-Site GMP Drug Substance Manufacturing Campaign for a Systemic AAV Gene Therapy: A Request-for-Proposal Framework for Technology Transfer and Process Performance Qualification
Qualifying a second drug substance site for a licensed gene therapy is among the most expensive and schedule-sensitive purchases a biologics sponsor makes, and an ambiguous request for proposal (RFP) multiplies both cost and risk. This article specifies an RFP for a contract development and manufacturing organization (CDMO) to receive the licensed suspension HEK293 triple-transfection process for a hypothetical systemic AAV gene therapy, run one non-GMP engineering batch and three consecutive GMP conformance lots at 2,000 L, validate transferred analytical methods, demonstrate comparability to the licensed process, and initiate stability studies. Technical parameters are given as illustrative starting limits subject to the licensed specification. The RFP sets a 21-month schedule with dependencies, an indicative budget of USD 24.0 to 33.5 million with an itemized structure, mandatory qualifications and a weighted scoring model, and regulatory obligations under 21 C.F.R. 601.12, ICH Q5E, and FDA gene therapy guidance. Recommendations address risk sharing for batch failure, ownership of process improvements, and confidentiality.Keywords: request for proposal; AAV; technology transfer; process performance qualification; comparability; CDMO; 21 C.F.R. 601.12
Authors
- Kishan Rajput
- Peivand Pirouzi
- Pruthvirajsinh Sindha
- Sukhpreet Singh Maan
- Vraj Modi
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24425226
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00